Had a short discussion with the company secretary. Key takeways:

1) Some demand on the volume side is getting affected due to fall in crude. I mentioned the point decreasing use of Enhanced Oil Recovery due to a drop in crude and whether that had an affect on demand - he said yes. He did allude to the fact that profits have still increased.
2) There aren't any client churning issues - no client has churned away and moved to competitors (clarified this as it was mentioned in one of the research reports)
3) He asked me to check the bse website as they have just submitted a disclosure today. As per the release: "Vinati Organics Ltd has informed BSE that the Company has entered into long term tripartite agreement with USA & Japan based Chemical Companies for supply of a customized product.Due to this turnover is expected to increase by Rs. 45 Crores in Financial year 2016-2017."

Hope this was helpful.

Regards

@diffsoft excellent work. No wonder Nifty can grow only at 10% or so.

Alembic has a 40.3% stake in Rhizen. Below is some copy-paste info from www.rhizen.com

Rhizen is a clinical-stage biopharmaceutical company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders. Rhizen’s proprietary IP in these areas is aimed at generating first-best-early in class, compounds that are expected to offer novel therapeutic options for these significant unmet medical needs. Rhizen operates as a virtual company leveraging the best efficiencies through out sourcing to globally reputed laboratories while progressing from pre-clinical to clinical development.

Rhizen’s business strategy involves collaborating /licensing with large pharmaceuticals companies for late stage clinical development and global marketing while focusing on pushing the research pipeline through preclinical and early human clinical development

Rhizen’s pipeline consists of internally discovered (with 100% IP ownership) novel small molecule programs aimed at high value markets of Oncology, Immuno-inflammtion and Metabolic Disorders. Rhizen has been successful in securing critical IP space in these areas and efforts are on for further expansion in to several indications. Rhizen seeks partnerships to unlock the potential of these valuable assets for further development from global pharmaceutical partners. At present global rights on all programs are available and Rhizen is flexible to consider suitable business models for licensing/collaboration.

Pasted image721x493 88 KB

Any idea how much stake Alembic have in Rhizen and how big could this opportunity be? Who own balance stake in Rhizen?

Will look up and get back on this.